To Study GSP 301 in Patients With Seasonal Allergic Rhinitis
- Conditions
- Seasonal Allergic Rhinitis
- Interventions
- Drug: GSP 301 Placebo NSDrug: GSP 301-1 NS (QD)Drug: GSP 301-2 NS (BID)
- Registration Number
- NCT02318303
- Lead Sponsor
- Glenmark Pharmaceuticals Ltd. India
- Brief Summary
Study to evaluate the two different strengths and dose regimen of GSP 301 to be effective in treatment of seasonal allergic rhinitis.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 1111
- Aged ≥12 years and older inclusive of either sex.
- Documented clinical history of SAR (for at least 2 years preceding the Screening Visit [Visit 1]) with exacerbations (clinical evidence of active symptoms) during the study season for the mountain cedar pollen
- A 12-hour reflective TNSS ≥ 8 out of a possible 12 and a congestion score of ≥ 2 for the AM assessment at the Screening Visit (Visit 1).
Key
- Pregnant or lactating women.
- Plans to travel outside the known pollen area for the investigative site for > 24 hours during the last 7 days of run in period.
- History of nasal polyps of other clinically significant respiratory tract malformations, recent nasal biopsy, nasal trauma (such as nasal piercing) or surgery, atopic dermatitis or rhinitis medicamentosa.
- History of anaphylaxis and/or other severe local reaction(s) to skin testing.
- History of positive test for HIV, Hepatitis B or Hepatitis C infection.
- Documented evidence of acute or significant chronic sinusitis or chronic purulent postnasal drip.
- Subjects with an active pulmonary disorder or infection.
- Subjects with posterior subcapsular cataracts or glaucoma.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description GSP 301 Placebo NS GSP 301 Placebo NS - GSP 301-1 NS (QD) GSP 301-1 NS (QD) - GSP 301-2 NS (BID) GSP 301-2 NS (BID) - Mometasone Furoate-1 NS (QD) Mometasone Furoate-1 NS (QD) - Mometasone Furoate-2 NS (BID) Mometasone Furoate-2 NS (BID) - Olopatadine HCl-1 NS (QD) Olopatadine HCl-1 NS (QD) - Olopatadine HCl-2 NS (BID) Olopatadine HCl-2 NS (BID) -
- Primary Outcome Measures
Name Time Method Change in rTNSS From Baseline to End of Treatment 14 days Subjects were asked to assess rTNSS (reflective Total Nasal Symptom Score), ie, an evaluation of symptom severity over the past 12 hours prior to the recording of the score. The TNSS was defined as the sum of the subject-reported symptom severity scores for the following four nasal symptoms, recorded by each subject in the diary: rhinorrhea, sneezing, nasal congestion, nasal itching.
The total rTNSS scores for all four symptoms (i.e, the lowest possible score (0) and the highest possible score (12).) Higher score means a worse outcome.
The severity scale for each symptom evaluation was defined as follows:
* 0 = absent (no sign/symptom evident)
* 1 = mild (sign/symptom clearly present, but minimal awareness; easily tolerated)
* 2 = moderate (definite awareness of sign/symptom that is bothersome but tolerable)
* 3 = severe (sign/symptom that is hard to tolerate \[i.e., causes interference with activities of daily living and/or sleeping\])
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (10)
Glenmark Investigational Site 1
🇺🇸Waco, Texas, United States
Glenmark Investigational Site 7
🇺🇸New Braunfels, Texas, United States
Glenmark Investigational Site 10
🇺🇸Austin, Texas, United States
Glenmark Investigational Site 4
🇺🇸San Antonio, Texas, United States
Glenmark Investigational Site 8
🇺🇸San Antonio, Texas, United States
Glenmark Investigational Site 9
🇺🇸San Antonio, Texas, United States
Glenmark Investigational Site 5
🇺🇸Austin, Texas, United States
Glenmark Investigational Site 6
🇺🇸Austin, Texas, United States
Glenmark Investigational Site 2
🇺🇸Kerrville, Texas, United States
Glenmark Investigational Site 3
🇺🇸San Antonio, Texas, United States